Spots Global Cancer Trial Database for Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Official Title: An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Study ID: NCT02709889
Study Description
Brief Summary: The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Detailed Description: This is a multicenter, open-label study involving multiple specific advanced solid tumor types, consisting of a dose escalation part A followed by an expansion part B. Cancer subtypes will be studied in separate disease-specific cohorts in both Parts. Eight separate cohorts will enroll malignant melanoma, medullary thyroid cancer (MTC), glioblastoma, large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatic neuroendocrine carcinoma (GEP NEC), other NEC, and solid tumors other than the above.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, Arizona, United States
Mayo Clinic - Scottsdale /ID# 155419, Scottsdale, Arizona, United States
University of California, Los Angeles /ID# 155429, Los Angeles, California, United States
Univ California, San Francisco /ID# 155409, San Francisco, California, United States
Cedars-Sinai Medical Center - West Hollywood /ID# 155428, West Hollywood, California, United States
Univ of Colorado Cancer Center /ID# 155415, Aurora, Colorado, United States
Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420, Denver, Colorado, United States
University of Florida - Archer /ID# 155414, Gainesville, Florida, United States
Moffitt Cancer Center /ID# 170220, Tampa, Florida, United States
Emory University Hospital /ID# 155417, Atlanta, Georgia, United States
University of Kentucky Chandler Medical Center /ID# 155423, Lexington, Kentucky, United States
Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States
Massachusetts General Hospital /ID# 155411, Boston, Massachusetts, United States
Dana-Farber Cancer Institute /ID# 171044, Boston, Massachusetts, United States
Mayo Clinic - Rochester /ID# 155416, Rochester, Minnesota, United States
Washington University-School of Medicine /ID# 155425, Saint Louis, Missouri, United States
Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States
University of New Mexico /ID# 205054, Albuquerque, New Mexico, United States
Roswell Park Comprehensive Cancer Center /ID# 162015, Buffalo, New York, United States
Weill Cornell Medical College /ID# 155418, New York, New York, United States
Duke University Medical Center /ID# 155421, Durham, North Carolina, United States
Univ Hosp Cleveland /ID# 155410, Cleveland, Ohio, United States
Oregon Health and Science University /ID# 162011, Portland, Oregon, United States
Greenville Hospital System /ID# 155427, Greenville, South Carolina, United States
Mary Crowley Cancer Research /ID# 162014, Dallas, Texas, United States
Texas Oncology - Forth Worth /ID# 162045, Fort Worth, Texas, United States
University of Texas MD Anderson Cancer Center /ID# 155413, Houston, Texas, United States
University of Utah /ID# 155426, Salt Lake City, Utah, United States
Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States
Northwest Cancer Specialists, P.C. /ID# 155431, Vancouver, Washington, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
